Americares, in partnership with the Healthcare Distribution Alliance, presented its annual Power of Partnership Award to Teva Pharmaceuticals in recognition of its outstanding commitment to ...

Teva 2024 Healthy Future Report: Health System Strengthening and Capacity Building Published 06-09-25 Submitted by Teva Pharmaceutical Patient who is part of the Global Hope Program in Uganda At Teva, ...

On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE: TEVA) with a Buy rating and a price target of $25.

Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.

Teva Pharmaceuticals' credit rating upgraded to BB+ by Fitch, reflecting debt reduction and positive growth outlook.

A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries 's (TEVA 1.75%) well higher on Monday.

Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30 ...

Shares of Teva Pharmaceutical (TEVA 1.19%) are surging on Wednesday. The company's stock is up 9.2% as of 1:15 p.m. ET and was up as much as 9.5% earlier in the day. The leg up comes as the S&P ...

In January 2025, Teva and Samsung Bioepis entered into a strategic partnership for the commercialization of EPYSQLI in the U.S. market. Under the terms of the agreement, Samsung Bioepis handles ...

Teva Pharmaceuticals’ share prices declined by 13.89 percent on Wednesday to finish at $18.54 each after announcing disappointing earnings guidance for 2025.